



Approved for use through 10/31/2002 OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Patent Information Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/024,678
		Filing Date	December 18, 2001
		First Named Inventor	David J. Yang
		Art Unit	3723
		Examiner Name	Not Yet Assigned
Sheet	1	of	3
		Attorney Docket Number	AH-UTXC:681US

RECEIVED
SEP 27 2002

TECHNOLOGY CENTER R370

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
bf	AA	6117949	09-12-2000	Rathi et al.	
bf	AB	6004573	12-21-1999	Rathi et al.	
bf	AC	5702717	12-30-1997	Cha et al.	
bf	AD	5257970	11-02-1993	Dougherty	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
bf	BA	JP-7097401A2	04-11-1995	Shiseido Co Ltd	
bf	BB	JP-1023698A2	09-08-1993	Hoechst Marion Roussel KK	
bf	BC	IB-00/38651	07-06-2000	Amgen Inc.	
bf	BD	IB-00/00222	01-06-2000	Amgen Inc.	

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
bf	CA	Burris III, Howard A., et al.; Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot center; Head Neck Surg; Vol. 118; pages 496 - 503; 1998			
bf	CB	Downs, Elizabeth C., et al.; Calcium Alginate Beads as a Slow-Release System for Delivering Angiogenic Molecules In Vivo and In Vitro; Journal of Cellular Physiology; Vol. 152; pages 422 - 429; 1991			
bf	CC	Smith, Jill P., et al.; Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts; Cancer Thermosther Pharmacol; Vol. 44; pages 267 - 274; 1999			
bf	CD	Ning, Shoucheng, et al.; Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system; Radiotherapy and Oncology; Vol. 50; pages 215 - 223; 1999			
bf	CE	Monga, Satdarshan P.S., et al.; Intratumoral Therapy of Cisplatin/Epinephrine Injectable Gel for Palliation in Patients With Obstructive Esophageal Cancer; Am J. Clin. Oncol.; Vol. 23(4); pages 386 - 392; 2000			
bf	CF	Miller, Bruce H., et al.; Nonsurgical treatment of basal cell carcinomas with intraleisional 5-fluorouracil/epinephrine injectable gel; Journal of the American Academy of Dermatology; Vol. 36 (1); pages 72 - 77; 1977			
bf	CG	Jackson, John K., et al.; The Suppression of Human Prostate Tumor Growth in Mice by the Intratumoral Injection of a Slow-Release Polymeric Paste Formulation of Paclitaxel; Cancer Research; Vol. 60; pages 4146 - 4151; 2000			
bf	CH	SPECT abnormalities in Landau-Kleffner syndrome; Journal of Clinical Neuroscience; Vol. 6 (1); pages 9 - 16; 1999			
bf	CI	Kitazawa, Hidenori, et al.; Microdialysis Assessment of Fibrin Glue Containing Sodium Alginate for Local Delivery of Doxorubicin in Tumor-Bearing Rats; Biol. Pharm. Bull.; Vol. 20			

25211917.1

RECEIVED

OCT 02 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/024,678
		Filing Date	December 18, 2001
		First Named Inventor	David J. Yang
		Group Art Unit	3723
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	AH-UTXC:681US
Sheet	2	of	3

		(3); pages 278 - 281; 1997	
AC	CJ	Kraus, Jorgen, et al.; Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene; Federation of European Biochemical Societies Letters; Vol. 428; pages 165 - 170; 1998	
AC	CK	Kuang, Liren, et al.; Percutaneous intratumoral injectino of cisplatin microspheres in tumor-bearing rats to diminish acute nephrotoxicity; Anti-Cancer Drugs; Vol. 7; pages 220 - 227; 1996	

Examiner Signature	Blessing Fubara	Date Considered	7-11-03
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.